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T
he clinical trial published in 
PLoS Medicine on whether 
male circumcision can 
prevent HIV (DOI: 10.1371/journal.
pmed.0020298) is a “landmark 
paper” in HIV research. So said the 
ﬁ  rst reviewer we sent this paper to. 
It is the ﬁ  rst randomized trial to be 
completed of circumcision for HIV 
prevention, a topic that has generated 
a huge amount of epidemiological 
research and argument since the 
ﬁ  rst observation that the incidence 
of HIV was lower in men who were 
circumcised. The trial was stopped at 
an interim analysis at the request of the 
trial’s data safety monitoring board. At 
a mean of 18.1 months’ follow-up there 
were 20 infections in the intervention 
(circumcised) group versus 49 in 
the control group, representing a 
protection of 60% (95% conﬁ  dence 
interval 32%–76%).
In many ways this trial is a paradigm 
for the whole of HIV research; it 
encompasses many of the practical, 
social, moral, and scientiﬁ  c difﬁ  culties 
of doing such research.
The ﬁ  rst, practical, problem of 
doing a trial that can test the effect 
of circumcision on preventing HIV 
infection is recruiting sufﬁ  cient 
numbers of individuals who are 
prepared to be circumcised, in an area 
where the event rate (new infections) 
is likely to be sufﬁ  ciently high that 
the trial can be done in a reasonable 
timeframe. It seems obvious, but 
perhaps not politically correct, to say 
that such a trial could not be done in 
New York or London or Paris. The trial 
we publish was done in South Africa, 
where the event rate is high and many 
African men now opt for circumcision 
in adult life by a medical practitioner. 
But this circumstance leads to the 
second, social, problem: the ethical 
issues involved in doing such a trial 
and of applying Western standards 
to a non-Western setting. People in 
developing countries do not want to 
be used by Western researchers to 
do trials that might not be allowed 
in their own countries. Trials should 
only be done that address crucial 
local health problems and in a way 
that is appropriate for each country, 
and potential participants should 
be included in discussions about 
what is acceptable to them. This trial 
fulﬁ  lls these criteria; however, HIV-
positive men were not excluded from 
participating nor were they told of 
their HIV status during the trial. The 
authors’ reasoning for not informing 
participants of their HIV status as a 
routine part of the trial (as would be 
likely if a similar trial could be done 
in a Western setting), and which was 
accepted by the two ethics boards that 
reviewed this trial, was as follows. In a 
country where there is stigma attached 
to being HIV positive, automatic 
exclusion of HIV-positive individuals 
would have potentially exposed them 
to discrimination. In addition, there 
may be beneﬁ  ts for HIV-positive 
individuals in being circumcised, 
including protection against other 
sexually transmitted diseases and 
against re-infection by other strains 
of HIV. At each visit all participants 
were offered advice on HIV and other 
sexually transmitted diseases and 
strongly encouraged to seek voluntary 
counseling and testing at a center 
close by where HIV status was disclosed 
to the patient if asked for. Although 
arguments rage over whether HIV 
status should be private or public 
knowledge, at the moment individuals 
cannot be forced into testing or 
indeed into knowledge of their status. 
Moreover, even if participants knew 
of their status, they would not have 
had access to antiretroviral drugs, 
as these were not available in South 
Africa when the trial was done. These 
ethical issues are discussed in two 
accompanying Perspectives: one by 
Peter Cleaton-Jones, chair of the 
South African ethics committee that 
approved the trial (DOI: 10.1371/
journal.pmed.0020287), and another 
by Nandi Siegfried (DOI: 10.1371/
journal.pmed.0020393). 
The ﬁ  nal problem that then arises 
is for editors: if you have any ethical 
questions about a study, should you 
publish it? This surely is what peer 
review and the editorial process is for. 
During the process of peer review here, 
ethical questions were raised and so 
also were scientiﬁ  c concerns. These 
concerns included the following: that 
the randomization used was unusual 
(but appropriate for this community); 
that participants were paid; that there 
were substantial numbers of dropouts; 
that the trial was stopped early (at 
the request of the data monitoring 
committee but, some might argue, too 
early for conclusive results); and that 
circumcision did appear to change the 
sexual behavior of participants—but in 
a way likely to make them more prone 
to infection, i.e., making the ﬁ  ndings 
more robust. In considering papers 
for publication editors must weigh all 
these issues and reviewers’ comments. 
We took particular note that this trial 
was approved by two experienced ethics 
boards. 
The six reviewers and the academic 
editor who saw this paper were 
unanimous on one point: that this trial 
must be published, quickly. Ultimately, 
if these results are correct, then this is a 
study that offers hope. Clearly, further 
randomized studies will be needed to 
conﬁ  rm the results (one in Kenya is 
scheduled for completion in 2007), 
but to not put this paper in the public 
domain quickly could be considered 
unethical in its own right.  
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